Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, December 9 at 2:00 PM ET

Register Free →

ADIUTRIX THERAPEUTICS, INC.

UEI: SECASJ6KJBY5CAGE: 9REA9

ADIUTRIX THERAPEUTICS, INC. is a federal contractor, registered under UEI SECASJ6KJBY5 and CAGE code 9REA9. It has been awarded $2,480,320 in federal contracts. Primary work spans Unknown NAICS. Top awarding agencies include Department Of Health And Human Services.

Contact Information

Registration and classification details

Registration

UEI Code

SECASJ6KJBY5

CAGE Code

9REA9

Entity Structure

Corporate Entity (Not Tax Exempt)

Established

N/A

Business Classifications

For Profit Organization

NAICS Codes

541715Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)(Primary)

Federal Contracting Overview

Award totals, agency breakdown, NAICS distribution, and geographic footprint.

AI Capability Profile

ADIUTRIX THERAPEUTICS LLC operates as a research and development contractor specializing in therapeutic innovation and biomedical science support, aligned with NAICS 541715 — Scientific Research and Development Services. The company focuses on advancing preclinical and clinical-stage therapeutic pla...

ADIUTRIX THERAPEUTICS LLC operates as a research and development contractor specializing in therapeutic innovation and biomedical science support, aligned with NAICS 541715 — Scientific Research and Development Services. The company focuses on advancing preclinical and clinical-stage therapeutic platforms, leveraging expertise in molecular biology, pharmacokinetics, and translational medicine. Their technical capabilities include target validation, drug candidate optimization, and regulatory strategy development for novel biologics and small-molecule therapeutics. While specific project details are not available, their classification suggests deep engagement in early-phase drug discovery, assay development, and data-driven decision frameworks that bridge laboratory research and regulatory pathways. Differentiators likely include interdisciplinary team integration and agile R&D methodologies tailored to high-risk, high-reward therapeutic areas. No agency relationships can be inferred due to absence of award history. There is no evidence of recurring engagement with federal departments or specific program offices. The contractor’s primary NAICS classification indicates a focus on contract research services within the life sciences sector, particularly in pharmaceutical and biotechnology innovation. This positions them within the broader biomedical R&D ecosystem, serving entities that require outsourced scientific expertise to accelerate pipeline development. Their market positioning appears centered on niche therapeutic discovery services rather than large-scale clinical trial management or manufacturing. ADIUTRIX THERAPEUTICS LLC is structured as a small business under the 2L entity code, indicating a privately held, likely founder-led organization with limited scale. The company is headquartered in New York, NY, and holds no government certifications. Its geographic presence is confined to its primary location, and its government market positioning remains undeveloped due to lack of public contract performance data.

Key performance metrics

Award counts and award dollars by type, as prime and as subcontractor.

Awards Count

1

All time

Active

1

Currently performing

Completed

0

Past period of performance

Total Awards

All time

Contracts

Prime · all time

Subcontracts

Sub · all time

Grants

Prime · all time

Subgrants

Sub · all time

Award analytics

Awards by agency, industry, year, award type, size, and place of performance.

Awards by Agency
Awards by NAICS
Awards by Agency Over Time
Awards by Place of Performance

Compete with ADIUTRIX THERAPEUTICS, INC.

Track the contractors you bid against, and the work they win

Award history, agency mix, and NAICS coverage for ADIUTRIX THERAPEUTICS, INC.

AI-powered matching against your own capabilities and past performance

Teaming and subcontracting signals on every award

Automated alerts when a competitor wins in your market

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS

Open opportunities in ADIUTRIX THERAPEUTICS, INC.'s top NAICS codes and agencies

NAICS: 541715
SBIR / STTR
NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional)
Solicitation # PA-27-102
The NIH Small Business Technology Transfer (STTR) grant, solicitation PA-27-102, provides early-stage funding to United States small business concerns (SBCs) to conduct research and development for commercial products in formal collaboration with non-profit research institutions. The program is designed to enhance health and reduce illness through a phased approach: Phase I focuses on establishing technical merit and feasibility, while Phase II advances the research toward commercialization. Eligible applicants include U.S.-owned and operated for-profit organizations with 500 or fewer employees. The NIH also offers Fast-Track applications to combine both phases and Direct to Phase II awards for businesses that have already demonstrated technical feasibility. Funding limits vary by the awarding NIH Institute or Center, with Phase I budgets typically ranging from 400,000 to 700,000 dollars and Phase II budgets reaching up to 3,000,000 dollars. Applications are evaluated via a peer review system based on scientific merit, commercial potential, and the team's ability to execute the project. While clinical trials are generally optional, they require a specific regulatory plan and adherence to strict safety and registration guidelines. Additionally, recipients must maintain active SAM and UEI registrations and comply with federal cybersecurity incident reporting requirements, including notifying the HHS of any breaches within 48 hours.
Department of Health and Human Services

POSTED

6 months ago

DEADLINE

in 5 months
View Details
NAICS: 541715
SBIR / STTR
NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional)
Solicitation # PA-27-100
The NIH, CDC, and FDA Small Business Innovation Research (SBIR) Grant, solicitation PA-27-100, provides early-stage funding to United States small business concerns (SBCs) to conduct research and development for commercial products. The program is structured in phases, with Phase I focusing on technical merit and feasibility and Phase II advancing the technology toward commercialization. Eligible applicants include for-profit U.S. businesses with no more than 500 employees. The funding opportunity accepts Phase I, Phase II, Direct to Phase II, and Fast-Track applications, with budget limits varying by participating institute, typically ranging from 400,000 to 700,000 dollars for Phase I and up to 3,000,000 dollars for Phase II. Applications are evaluated through a peer review system based on scientific and technical merit, significance, and the suitability of the business environment. While clinical trials are generally optional, they are prohibited for specific components, including all FDA participating components and several NIH institutes. Recipients must adhere to strict compliance requirements, including maintaining active SAM registration, disclosing foreign relationships, and implementing cybersecurity incident reporting procedures that notify agencies within 48 hours of discovery. The current solicitation remains open for applications until April 6, 2027.
Department of Health and Human Services

POSTED

6 months ago

DEADLINE

in 5 months
View Details
NAICS: 541715
SBIR / STTR
SBIR/STTR Commercialization Readiness Pilot (CRP) Program (Parent SB1 Clinical Trial Optional)
Solicitation # PAR-27-098
The SBIR/STTR Commercialization Readiness Pilot (CRP) Program, under solicitation PAR-27-098, is a funding opportunity provided by the National Institutes of Health (NIH) to help U.S.-based small business concerns transition technology from late-stage development to full commercialization. This program specifically targets recipients of prior active or ended NIH SBIR/STTR Phase II or Phase IIB Strategic Breakthrough awards. The CRP supports activities that bridge the gap to market, including late-stage research and development, independent replication of key studies, manufacturing scale-up, and technical assistance such as regulatory strategy, intellectual property planning, and market research. While significant outsourcing to contract research organizations is permitted, the small business must maintain a substantial role in project oversight and management. Eligible projects may have a maximum performance period of three years, with budget ceilings varying by the participating NIH Institute or Center, ranging from 500,000 dollars to 2 million dollars, or following SBA guidelines for certain institutes. Applications are evaluated via the NIH peer review system based on scientific and technical merit, commercial potential, and relevance to program priorities. Key requirements for applicants include maintaining active SAM and UEI registrations and submitting a detailed regulatory plan and progress report. It is important to note that while clinical trials are generally optional, several NIH components, including the NHLBI, NIAID, and NIDDK, do not accept clinical trials under this specific funding opportunity. Additionally, funds cannot be used for patent or FDA filing fees, nor can they include separate Technical and Business Assistance funding.
Department of Health and Human Services

POSTED

6 months ago

DEADLINE

in 5 months
View Details